Live Webinar: Preventive Treatment for Alzheimer's Disease
In this webinar presented by the Mount Sinai Medical Center of Florida on the 30th of November, 2012, three international experts in the field of Alzheimer's disease had presented:
How genetic and other factors can determine when amyloid protein is deposited in the brain, resulting in symptoms of Alzheimer's disease many years later
Why effective treatment of Alzheimer's disease may need to begin very early, well before symptoms are present
How new treatment trials, which will begin in 2013, are being designed for the prevention of Alzheimer's disease
The presentations were followed by panel discussion along with a Q&A session.
The event was open to and free for all.
PLEASE REVIEW THE RECORDING OF THE SESSION:
PLEASE REVIEW THE SLIDE PRESENTATIONS:
Jessica Langbaum, Ph.D.
Banner Alzheimer's Institute
Dr. Langbaum, a principal scientist at Banner Alzheimer's Institute, earned a bachelor's degree in neuroscience and psychology with high honors from Oberlin College in Oberlin, Ohio, and a Ph.D. in psychiatric epidemiology from the Johns Hopkins University. Her doctoral studies focused on cognition and aging in older adults, in particular, cognitive training interventions for delaying or preventing cognitive and functional decline. She completed a post-doctoral research fellowship in brain imaging and Alzheimer's disease at Banner Alzheimer's Institute.
She is actively involved in research activities focusing on the use of brain imaging for studying the earliest evidence of Alzheimer's and on the design and execution of presymptomatic Alzheimer's treatment trials. Dr. Langbaum has published papers in leading scientific journals on cognitive training, brain imaging and Alzheimer's disease.
Andrew Saykin, Psy.D.
Raymond C. Beeler Professor of Radiology and Imaging Sciences
Indiana University School of Medicine
Dr. Saykin joined the Indiana University School of Medicine faculty in November 2006 as director of a new transdisciplinary center of excellence in neuroimaging. The goals of the center are: 1) to utilize imaging technologies to advance the understanding of brain function and anatomy in healthy and clinical populations and though translational studies of animal models; 2) to investigate the relationship between genetic variation and phenotypic expression structurally and functionally in health, illness, and following treatment; 3) to provide training and experience in advanced brain imaging research methods; and 4) to develop, assess, and validate emerging technologies that optimize the use of molecular and functional imaging methodologies including PET, fMRI, DTI, MRS, perfusion and morphometry as well as image analysis strategies and bioinformatics.
Dr. Saykin's own NIH and foundation sponsored research program focuses on the use of brain imaging and genomic methods to study mechanisms of memory dysfunction and treatment response in neurological and psychiatric disorders. Current projects examine advanced imaging methods for early preclinical detection of Alzheimer's disease (NIA R01 AG19771), the neural basis of cancer chemotherapy-induced cognitive changes (NCI R01 CA101318), and alterations in brain activity and connectivity in schizophrenia (U54 EB005149). Each project includes a component examining genomic correlates of brain imaging phenotypic markers.
Susan M. Landau, Ph.D.
Helen Wills Neuroscience Institute
University of California, Berkeley
Lawrence Berkeley National Laboratory
Susan Landau, PhD is a Research Neuroscientist at the Helen Wills Neuroscience Institute at the University of California, Berkeley and the Lawrence Berkeley National Laboratory. Her research focuses on the longitudinal evaluation of multiple biomarkers in aging, mild cognitive impairment, and Alzheimer's disease. Recent work with the Alzheimer's Disease Neuroimaging Initiative (ADNI) has examined the predictive role of amyloid PET and FDG-PET imaging, and other genetic, cerebrospinal fluid, and imaging biomarkers in cognitive decline at different phases of disease. Other recent work has examined the role of cognitive activity and lifestyle factors in aging and amyloid deposition, and the impact of chemotherapy on neural and cognitive function.
Dr. Landau studied cognitive psychology and neuroscience at Wesleyan University and completed an MA and PhD at UC Berkeley, where she received a National Science Foundation Graduate Research Fellowship award. She has carried out research on learning, working memory, and dopamine in healthy aging and dementia using PET and functional MRI. She has received additional training in cognitive neuroscience and neuroimaging at Dartmouth University, in neuropsychological evaluation at the Memory and Aging Center at the University of California San Francisco, and in electrophysiology at the Center for the Neural Basis of Behavior at the University of Pittsburgh.